Medicare Will Boost Physician Reimbursement For Sharing COVID-19 Clinical Trial Data
Participants in CMS's Quality Payment Program can earn credit to boost their Medicare reimbursements by reporting information from COVID-19 drug trials through a clinical trial repository or registry; NIH issues treatment guidelines for the coronavirus that are to be continuously updated.
You may also be interested in...
CMS Doubles Up On Test Reimbursements, Will Pay Labs $100 Per Test For COVID-19 Clinical Diagnostic Assays
The US Medicare agency said on 15 April it will double its reimbursement rate for certain COVID-19 lab tests.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.